Clinical Trial: Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Study Status: Completed
Recruit Status: RECRUITING
Condition: Non Small Cell Lung Cancer
Study Type: INTERVENTIONAL
Official Title: A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mu
Brief Summary:
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation.The main question[s] it aims to answer are:the recommended dose for Phase 2to evaluate the safety and tolerability of the combination therapyto determine the pharmacokinetics of TNG260to evaluate the initial antineoplastic activityParticipants will receive study treatment until they experience an undesirable side effect,…
Read more